Sintilimab in Combination with Anlotinib as First-Line Therapy for Advanced NSCLC: Final Analysis of Primary Endpoints

被引：0
|
作者：
Han, B. [1 ]
Chu, T. [1 ]
Zhong, R. [1 ]
Zhong, H. [1 ]
Zhang, B. [1 ]
Zhang, W. [1 ]
Shi, C. [1 ]
Qian, J. [1 ]
Zhang, Y. [1 ]
Chang, Q. [1 ]
Zhang, X. [1 ]
Dong, Y. [1 ]
Teng, J. [1 ]
Gao, Z. [1 ]
Qiang, H. [1 ]
Nie, W. [1 ]
Zhao, Y. [1 ]
Han, Y. [1 ]
Chen, Y. [1 ]
机构：
[1] Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
multi-target angiogenic TKI; chemo-free; PD-1; inhibitor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA07.09
引用
收藏
页码：S119 / S119
页数：1
相关论文
共 50 条
  • [1] Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
    Chu, Tianqing
    Zhong, Runbo
    Zhong, Hua
    Zhang, Bo
    Zhang, Wei
    Shi, Chunlei
    Qian, Jialin
    Zhang, Yanwei
    Chang, Qing
    Zhang, Xueyan
    Dong, Yu
    Teng, Jiajun
    Gao, Zhiqiang
    Qiang, Huiping
    Nie, Wei
    Zhao, Yiming
    Han, Yuchen
    Chen, Ya
    Han, Baohui
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : 643 - 652
  • [2] Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Zhong, R.
    Zhong, H.
    Zhang, B.
    Zhang, W.
    Shi, C.
    Qian, J.
    Han, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S129 - S129
  • [3] Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
    Chen, X.
    Li, W.
    Wu, X.
    Zhao, F.
    Wu, H.
    Gu, Y.
    Li, X.
    Qian, X.
    Hu, J.
    Li, C.
    Xia, Y.
    Yao, A.
    Seesaha, P. K.
    Shao, Q.
    Dong, X.
    Li, X.
    Shu, Y.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1305 - S1305
  • [4] Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC).
    Chen, Xiaofeng
    Li, Wei
    Wu, Xiaofeng
    Zhao, Fengjiao
    Wang, Deqiang
    Wu, Hao
    Gu, Yanhong
    Li, Xiao
    Qian, Xiaofeng
    Hu, Jun
    Li, Changxian
    Xia, Yongxiang
    Rao, Jianhua
    Yao, Aihua
    Seesaha, Poshita Kumari
    Shao, Qianwen
    Dong, XiaoWei
    Li, Xiangcheng
    Shu, Yongqian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
    Jin, Y.
    Yu, X.
    Fan, Y.
    He, X. Q.
    Lin, C.
    Hong, W.
    Gu, C.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1656 - S1657
  • [6] Bevacizumab in the first-line therapy of advanced NSCLC
    Hasenoehrl, Norbert
    [J]. WIENER MEDIZINISCHE WOCHENSCHRIFT, 2007, 157 (21-22) : 576 - 578
  • [7] A Multicenter, Randomized, Phase 3 Trial of Penpulimab in Combination With Anlotinib or Chemotherapy as First-Line Treatment in Advanced NSCLC
    Han, B.
    Chen, J.
    Xie, Q.
    Yao, W.
    Shi, H.
    Zhao, Y.
    Song, W.
    Jin, X.
    Wang, Z.
    Li, B.
    Xia, Y.
    Jiao, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S650 - S650
  • [8] Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Han, B.
    Chu, T.
    Zhang, X.
    Zhong, H.
    Zhang, B.
    Wang, H.
    Gu, A.
    Zhang, W.
    Shi, C.
    Zhong, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S398 - S398
  • [9] Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis
    OuYang, Pu-Yun
    Su, Zhen
    Mao, Yan-Ping
    Deng, Wuguo
    Xie, Fang-Yun
    [J]. PLOS ONE, 2013, 8 (11):
  • [10] First-line combination therapy versus first-line monotherapy for primary hypertension
    Garjon, Javier
    Carlos Saiz, Luis
    Azparren, Ana
    Gaminde, Idoia
    Jose Ariz, Ma
    Erviti, Juan
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (02):
12345